International Journal of Thyroidology

Indexed in /covered by CAS, KoreaScience & DOI/Crossref:eISSN 2466-1899   pISSN 2384-3799

Table. 1.

Table. 1.

Baseline characteristics of patients

Total No post-EA RAI treatment group Post-EA RAI treatment group
Patients (n) 42 23 19
Sex (n/% female) 25/59.52% 15/62.5% 10/55.55%
Age, years (mean±SD) 48.34±18.03 46.05±17.46 51.13±19.62*
Time from surgery to EA, years (mean/range) 3.72/0.5-18.0 3.83/0.5-18.0 3.54/0.5-6.3
Lateral neck dissection (n) 17 5 12
Rescue surgery´╝őRAI (n) 13 3 10
RAI dose, mCi (mean±SD) 160.23±88.28 118.69±52.07 210.52±98.00*
Patients with Tg-Ig 4 1 3
TNM postoperative stage (n)
I 23 16 7
II 8 5 3
III 5 1 4
IVA 6 1 5
IVB 0 0 0
Histology
Classic PTC 23 14 9
PTCFV 5 3 2
PDPTC 1 0 1
MPTC 1 1 0
MFPTC 7 5 2
PTC with aggressive histology§ 3 0 3
FTC 1 0 1
Oncocytic variant FTC 1 0 1

EA: ethanol ablation, FTC: follicular thyroid carcinoma, mCi: millicurie, MFPTC: multifocal papillary thyroid carcinoma, MPTC: micropapillary thyroid carcinoma, PDPTC: poorly differentiated papillary thyroid carcinoma, PTC: papillary thyroid carcinoma, PTCFV: papillary thyroid carcinoma follicular variant, RAI: radioactive iodine, SD: standard deviation, Tg-Ig: thyroglobulin antibodies

§Aggressive histology included one case with tall cell variant PTC and two cases with diffuse sclerosing variant PTC.

*p<0.05 (two-sided t-Student)

Int J Thyroidol 2020;13:128-41 https://doi.org/10.11106/ijt.2020.13.2.128
© 2020 Int J Thyroidol